Fulcrum Therapeutics (FULC) Earnings Date, Estimates & Call Transcripts $7.03 +0.07 (+1.01%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$7.04 +0.00 (+0.07%) As of 06/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Fulcrum Therapeutics Earnings Summary Fulcrum Therapeutics announced Q1 2025 earnings on May 1, 2025, reporting an EPS of -$0.28, which beat the consensus estimate of -$0.29 by $0.01. With a trailing EPS of -$0.07, Fulcrum Therapeutics' earnings are expected to decrease next year, from ($0.16) to ($1.08) per share. Upcoming Q2 Earnings DateJul. 30Before Market OpensEstimatedConsensus EPS (May. 1) -$0.29 Actual EPS (May. 1) -$0.28 Beat By $0.01 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)FULC Upcoming EarningsFulcrum Therapeutics' next earnings date is estimated for Wednesday, July 30, 2025, based on past reporting schedules. Powered by Get Fulcrum Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataFULC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FULC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Fulcrum Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.35-$0.27-$0.31Q2 20252-$0.34-$0.28-$0.31Q3 20252-$0.33-$0.29-$0.31Q4 20252-$0.32-$0.32-$0.32 Fulcrum Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 7/30/2025(Estimated)--------5/1/2025Q1 2025-$0.29-$0.28+$0.01-$0.28--2/25/2025Q4 2024-$0.28-$0.31 -$0.03-$0.31--7/31/2024Q2 2024-$0.06$0.87+$0.93$0.87$80.00M$80.00M5/13/2024Q1 2024-$0.44-$0.43+$0.01-$0.43--2/27/2024Q4 2023-$0.44-$0.40+$0.04-$0.40$0.65M$0.87M11/7/2023Q3 2023-$0.44-$0.39+$0.05-$0.39$1.81M$0.76M8/3/2023Q2 2023-$0.44-$0.38+$0.06-$0.38$1.60M$0.88M Fulcrum Therapeutics Earnings - Frequently Asked Questions When is Fulcrum Therapeutics's earnings date? Fulcrum Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 30th, 2025 based off last year's report dates. Learn more on FULC's earnings history. Did Fulcrum Therapeutics beat their earnings estimates last quarter? In the previous quarter, Fulcrum Therapeutics (NASDAQ:FULC) reported ($0.28) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.29) by $0.01. Learn more on analysts' earnings estimate vs. FULC's actual earnings. How can I listen to Fulcrum Therapeutics's earnings conference call? The conference call for Fulcrum Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Fulcrum Therapeutics's conference call transcript? The conference call transcript for Fulcrum Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Fulcrum Therapeutics generate each year? Fulcrum Therapeutics (NASDAQ:FULC) has a recorded annual revenue of $80 million. How much profit does Fulcrum Therapeutics generate each year? Fulcrum Therapeutics (NASDAQ:FULC) has a recorded net income of -$97.33 million. FULC has generated -$0.07 earnings per share over the last four quarters. What is Fulcrum Therapeutics's EPS forecast for next year? Fulcrum Therapeutics's earnings are expected to decrease from ($0.16) per share to ($1.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies 89bio Earnings Adaptive Biotechnologies Earnings Dyne Therapeutics Earnings Vera Therapeutics Earnings ANI Pharmaceuticals Earnings Calliditas Therapeutics AB (publ) Earnings Ocular Therapeutix Earnings Amphastar Pharmaceuticals Earnings Aurinia Pharmaceuticals Earnings Mineralys Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ollie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns? This page (NASDAQ:FULC) was last updated on 6/4/2025 by MarketBeat.com Staff From Our PartnersThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Recession Already Started, Are You Prepared?Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
